Dianthus Therapeutics Inc (DNTH) saw an uptrend of 14.67% in the recent trading with $44.86 being its most recent. The current price level -1.31% lower than the highest price of $45.46 marked by the stock while trading over the past 52-weeks, whereas it is 235.65% higher than the lowest price of $13.36 the company dropped to over past 52-weeks. The latest news story on DNTH appeared in (GlobeNewswire) under the title “Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 6 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.13 for the stock.
Dianthus Therapeutics Inc Earnings – What Happened With DNTH
Coming around sales and income figures on DNTH Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Dianthus Therapeutics Inc (DNTH) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 7.91% for net revenue.
DNTH – Dianthus Therapeutics Inc Stock Earnings Estimates
The perspective of Dianthus Therapeutics Inc (NASDAQ:DNTH)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.76 for stock’s EPS in the current quarter. Dianthus Therapeutics Inc (DNTH) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 7.91% for net revenue. Company’s EPS for the last quarter was -0.7.
Dianthus Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 42.85 million. DNTH does have institutional investors; and they hold 92.73% of the stock.
As on 2024-06-30, FMR LLC was the top most holder in Dianthus Therapeutics Inc (NASDAQ:DNTH) with an ownership of 4.4 million shares of the company or 12.8624 of the stake worth $113.93 million. The filing also reveals BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC as the second largest holder in the company with a control over 8.8042 of the outstanding shares. Its stake is worth $77.99 million for having 3.01 million shares in hand.
AVIDITY PARTNERS MANAGEMENT LP also came holding a key position in the company during the recent quarter and it now holds 8.5232 of the outstanding shares. With this there are now 203.0 institutions which have possession in DNTH’s shares.
Key Metrics for DNTH
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Dianthus Therapeutics Inc has a debt to equity ratio of 0.00.
